FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average b	urden							
- 1	ha	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					0.	000	00(	11) 01 1110	IIIVCStilicii			00.0							
1. Name and Address of Reporting Person*  Hannah Brendan					2. Issuer Name and Ticker or Trading Symbol Quince Therapeutics, Inc. [ QNCX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last)	`	irst) RAPEUTICS, IN	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/04/2024								below	officer (give title elow)  F BUSINESS		Other (s below) CER ANI		
611 GATEWAY BLVD, SUITE 273					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SOUTH SAN FRANCISCO CA 94080														Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				_   R	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - Nor	n-Deri	vativ	e Se	curit	ies Ac	quired,	Dis	osed o	f, or Be	neficia	lly Owne	t				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date		, Transaction Disp Code (Instr. 5)		Dispose	ecurities Acquired (A) o losed Of (D) (Instr. 3, 4		Benefic Owned	es ially Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			Instr. 4)	
Common Stock 06/04/					04/202	/2024		M		56,061 A		\$0.5	55 25	257,616		D			
			Table II -						,		,	or Bend ble secu		/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisab		expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (right to	\$0.55	06/04/2024			M			56,061	(1)	0	3/27/2032	Common Stock	56,061	\$0	47,43	9	D		

## Explanation of Responses:

1. The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.

/s/ Brendan Hannah

06/05/2024

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).